お知らせ • Jul 16
Panacea Life Sciences Holdings, Inc. Files Form 15 Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share. お知らせ • Jun 13
Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 30,000,000
Price\Range: $0.05 to $0.2
Discount Per Security: $0 お知らせ • Oct 07
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023. お知らせ • Aug 17
Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filing On 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Aug 03
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea. お知らせ • Jul 12
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022.
Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders. お知らせ • Jan 24
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. お知らせ • Jul 24
Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of Directors Panacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position. お知らせ • Jul 15
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID Panacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market. お知らせ • Aug 18
Exactus, Inc. announced delayed 10-Q filing On 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.